BioStem Technologies, Inc. (BSEM)
| Market Cap | 84.11M -55.9% |
| Revenue (ttm) | 47.48M -84.3% |
| Net Income | -6.58M |
| EPS | -0.39 |
| Shares Out | 16.86M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 63,842 |
| Average Volume | 56,254 |
| Open | 4.970 |
| Previous Close | 4.920 |
| Day's Range | 4.900 - 5.350 |
| 52-Week Range | 3.093 - 15.740 |
| Beta | -0.00 |
| RSI | 44.01 |
| Earnings Date | Mar 24, 2026 |
About BioStem Technologies
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human conne... [Read more]
Financial Performance
Financial StatementsNews
BioStem Technologies, Inc. (BSEM) Q4 2025 Earnings Call Transcript
BioStem Technologies, Inc. (BSEM) Q4 2025 Earnings Call Transcript
BioStem Appoints Jodi Ungrodt to Board of Directors as Audit Committee Chair
SEC-Qualified Financial Expert and Life Sciences Veteran Brings 29 Years of Accounting Leadership to the Board SEC-Qualified Financial Expert and Life Sciences Veteran Brings 29 Years of Accounting Le...
BioStem Technologies, Inc. (BSEM) M&A Call Transcript
BioStem Technologies, Inc. (BSEM) M&A Call Transcript
BioTissue Holdings, Inc Strengthens Strategic Focus on Ocular Innovation with Sale of Surgical and Wound Care Business to BioStem Technologies
BioTissue Deepens Commitment to Ocular Market Leadership MIAMI, Jan. 21, 2026 /PRNewswire/ -- BioTissue Holdings, Inc, a leader in harnessing the unique properties of human birth tissue to facilitate ...
BioStem Technologies, Inc. (BSEM) Q3 2025 Earnings Call Transcript
BioStem Technologies, Inc. (OTCPK:BSEM) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Philip Taylor - Associate Jason Matuszewski - CEO, President, Secretary & Chairman Bran...
BioStem Technologies Appoints KPMG as its Independent Registered Public Accountant
POMPANO BEACH, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM) (the “Company”), a leading MedTech company focused on the development, manufacturing, and commercializatio...
BioStem Technologies, Inc. (BSEM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
BioStem Technologies, Inc. (OTCPK:BSEM) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 3:20 PM EDT Company Participants Jason Matuszewski - CEO, President, Secretary & Chai...
BioStem Technologies, Inc. (BSEM) Q2 2025 Earnings Call Transcript
BioStem Technologies, Inc. (OTCPK:BSEM) Q2 2025 Earnings Conference Call August 14, 2025 4:30 PM ET Company Participants Adam Holdsworth - Corporate Participant Brandon Poe - Corporate Participant Jas...
BioStem Technologies: Huge Growth, Poised To Help Wound Care Field
BioStem Technologies is a buy due to strong YoY growth, profitability, and undervaluation versus sector peers despite recent Q1 misses. Their advanced wound care products, powered by proprietary BioRE...
BioStem Technologies, Inc. (BSEM) Q1 2025 Earnings Call Transcript
BioStem Technologies, Inc. (OTCPK:BSEM) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants Adam Holdsworth - Director-Investor Relations Jason Matuszewski - Chief Executive ...
BioStem Technologies, Inc. (BSEM) Q4 2024 Earnings Call Transcript
BioStem Technologies, Inc. (OTCPK:BSEM) Q4 2024 Earnings Conference Call April 14, 2025 4:30 PM ET Company Participants Adam Holdsworth - Investor Relations Jason Matuszewski - Chief Executive Officer...
BioStem Announces Notice of Allowance for Two U.S. Patent Applications
POMPANO BEACH, Fla., March 31, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-...
BioStem Technologies: Building On Advanced Wound Care Needs
BioStem Technologies' falling share price and rising earnings present a growth opportunity, supported by strong Q4 results, new products, and a potential NASDAQ listing. Q4-2024 revenue expected to ri...
BioStem Technologies Launches Clinical Trial to Demonstrate the Therapeutic Benefits of its BioREtain® Technology in Treating Diabetic Foot Ulcers Using Vendaje®
POMPANO BEACH, Fla., Jan. 08, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-d...
BioStem Technologies CEO to Present at Biotech Showcase 2025
POMPANO BEACH, Fla., Jan. 02, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-d...
Long-Term, BioStem Technologies Still A Promising Growth Stock
BioStem Technologies has experienced significant price volatility, driven by positive news and uplisting plans, but recent profit-taking has caused a pullback. Q3 earnings report showed impressive gro...
BioStem Technologies, Inc. (BSEM) Q3 2024 Earnings Call Transcript
BioStem Technologies, Inc. (OTCPK:BSEM) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Adam Holdsworth - Investor Relations Jason Matuszewski - Chief Executive Offi...
BioStem Technologies to Present at the LD Micro Main Event XVII on Wednesday, October 30, 2024, at 9:30 AM PT
Presentation to be webcast, with management participating in 1-on-1 meetings at the Luxe Sunset Boulevard Hotel in Los Angeles Pompano Beach, Florida--(Newsfile Corp. - October 23, 2024) - BioStem Tec...
BioStem Technologies, Inc. to Present at the H.C. Wainwright 26th Annual Global Investment Conference in New York on September 9th at 3:30 PM ET
POMPANO BEACH, Fla., Aug. 29, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-der...
BioStem Technologies: A New Growth Star In Health Care
BioStem Technologies has enjoyed exceptional growth in its first year as a public company, with revenues soaring and earnings turning positive. The company's flagship product, AmnioWrap2, has been a m...
BioStem Technologies, Inc. (BSEM) Q2 2024 Earnings Call Transcript
BioStem Technologies, Inc. (OTCPK:BSEM) Q2 2024 Results Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants Adam Holdsworth - Investor Relations Jason Matuszewski - Chief Executiv...
BioStem Technologies Inc. In A Race To The Top With Innovative Wound-Care Treatments
Miami, Florida--(Newsfile Corp. - July 16, 2024) - Innovation is the lifeblood of the MedTech sector. Literally.
UPDATE -- PRISM MarketView Showcases BioStem Technologies: Impressive Revenue Growth and Strategic Expansion
Please note: this Update is being issued for ticker indexing purposes. The content of the release itself remains the same.
PRISM MarketView Showcases BioStem Technologies: Impressive Revenue Growth and Strategic Expansion
NEW YORK, June 17, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView presents an exclusive interview with Jason Matuszewski, CEO of BioStem Technologies, Inc. ( OTC: BSEM). Following a successful start to 20...
Biostem Technologies, Inc. (BSEM) Q1 2024 Earnings Call Transcript
Biostem Technologies, Inc. (OTCPK:BSEM) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Jeff Ramson - IR, PCG Advisory Group Jason Matuszewski - Chief Executive Officer M...